+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Minimally Invasive Glaucoma Surgery Devices Market by Mechanism (Canaloplasty, Subconjunctival Filtration, Suprachoroidal Shunts), End User (Ambulatory Surgery Centers, Hospital, Ophthalmic Clinics), Distribution Channel, Indication - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 191 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 4968801
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Minimally Invasive Glaucoma Surgery Devices Market grew from USD 526.62 million in 2024 to USD 555.41 million in 2025. It is expected to continue growing at a CAGR of 5.42%, reaching USD 722.94 million by 2030.

Exploring the Evolution of Minimally Invasive Glaucoma Surgery Devices and Their Emerging Role in Enhancing Patient Outcomes Across Diverse Ophthalmic Settings

Minimally invasive glaucoma surgery devices have emerged as a paradigm shift in ophthalmic care, offering patients and clinicians novel approaches that balance efficacy with safety. Recent innovations in device design and surgical technique have accelerated the adoption of these solutions, leading to more targeted interventions that preserve tissue integrity while effectively reducing intraocular pressure.

As clinical trials have validated the benefits of microincisional procedures, the field has expanded to include a diverse array of platforms that cater to specific anatomical and pathological considerations. In parallel, regulatory bodies across major regions have refined their approval pathways to accommodate incremental advancements, fostering a more dynamic environment for research and development.

This introduction outlines the scope of the executive summary, framing key themes such as technological evolution, market dynamics, and strategic implications. It lays the groundwork for deeper analysis by highlighting the importance of understanding both clinical impact and market catalysts, setting the stage for informed decision-making by manufacturers, healthcare providers, and investors.

Unveiling Key Technological and Clinical Advances That Are Rapidly Reshaping the Minimally Invasive Glaucoma Surgery Device Ecosystem

The landscape of minimally invasive glaucoma surgery has undergone transformative shifts driven by cross-disciplinary innovation and patient-centric design principles. Advances in microcatheter technology and filtration pathways have enabled devices that target Schlemm’s canal, subconjunctival spaces, and suprachoroidal routes with unprecedented precision. Consequently, clinicians now benefit from a broader toolkit that can be tailored to the unique needs of individuals with varying disease severities and anatomical profiles.

Moreover, the convergence of digital surgical planning and real-time intraoperative imaging has elevated procedural accuracy, reducing postoperative complications while streamlining workflow efficiencies. In parallel, strategic collaborations between ophthalmic device developers and surgical centers have accelerated the translation of novel concepts into commercial products, reinforcing the trajectory toward minimally invasive interventions.

Ultimately, these transformative shifts underscore a new era in glaucoma management, where incremental technological refinements rapidly accumulate to produce holistic improvements in patient quality of life, clinical outcomes, and health economics.

Assessing the Operational and Strategic Implications of Newly Enforced United States Tariffs on Importation and Manufacturing Costs in 2025

The implementation of new United States tariffs in 2025 has introduced an additional layer of complexity for manufacturers and suppliers of minimally invasive glaucoma surgery devices. As import duties have been adjusted, stakeholders must closely examine their supply chain strategies to mitigate cost impacts. Procurement teams are adapting by exploring alternative sourcing arrangements and renegotiating contracts to preserve margin structures while maintaining compliance with trade regulations.

In response, some companies have localized production or established assembly hubs in regions unaffected by the revised tariff schedule. These initiatives not only address duty-related expenditures but also align with broader efforts to enhance supply chain resilience and reduce lead times. Additionally, by investing in domestic manufacturing infrastructure, firms position themselves to capitalize on government incentives that support onshore production of high-value medical devices.

Looking forward, sustained vigilance and proactive engagement with policymakers will be critical to navigate potential modifications to trade policies. Organizations that successfully integrate tariff considerations into their broader market strategies will be better equipped to sustain competitive pricing, ensure reliable product availability, and safeguard long-term growth in the U.S. market.

Revealing In-Depth Segmentation of Clinical Approaches End Users Distribution Channels and Indications to Inform Targeted Market Positioning Strategies

Analysis by mechanism reveals that interventions spanning canaloplasty, subconjunctival filtration, suprachoroidal shunts, and trabecular micro-bypass each occupy distinct clinical niches. Canaloplasty approaches, exemplified by microcatheter systems delivering viscodilation, coexist alongside specialized kits that address outflow resistance. Meanwhile, implants tailored for subconjunctival filtration have emerged to facilitate controlled subconjunctival drainage, augmenting approaches that reroute aqueous humor beyond the trabecular meshwork.

Devices designed for suprachoroidal implantation leverage the natural uveoscleral pathway, offering an alternative route for pressure alleviation while mitigating conjunctival disturbance. Concurrently, trabecular micro-bypass innovations provide direct access to Schlemm’s canal, with microstents and dual-edged blades facilitating precise tissue excision or scaffold placement. These mechanistic distinctions inform both clinical decision-making and product positioning.

From an end-user perspective, ambulatory surgery centers, hospitals, and dedicated ophthalmic clinics each present unique procedural volumes, reimbursement frameworks, and adoption curves. Product distribution further varies between direct tender arrangements with healthcare systems and collaborations with specialized distributors that service community practices.

Finally, patient indications ranging from ocular hypertension to primary open-angle glaucoma and secondary glaucomas define the therapeutic urgency and clinical pathways for device selection. This multi-layered segmentation highlights the necessity of aligning product attributes with the specific demands of surgeons, institutions, and patient cohorts.

Mapping the Varied Regulatory Reimbursement and Clinical Adoption Patterns Across the Americas EMEA and Asia-Pacific Regions

Regional dynamics in the minimally invasive glaucoma surgery landscape reflect a tapestry of clinical preferences, regulatory environments, and payer structures. In the Americas, robust healthcare infrastructure and established reimbursement models have facilitated early uptake of microinvasive procedures, supported by key opinion leader networks and consortium-based training initiatives.

Across Europe, the Middle East, and Africa, heterogeneity in approval processes and budgetary constraints has led manufacturers to adopt flexible launch strategies, often partnering with regional distributors to navigate diverse market entry requirements. Stakeholders in this collective region prioritize incremental innovation that demonstrates clear value propositions to national health authorities and private insurers alike.

Meanwhile, the Asia-Pacific region embodies a rapidly evolving landscape where growing awareness of minimally invasive options converges with expanding surgical capacity. Local manufacturers and multinational corporations alike are investing in clinical education programs to cultivate skilled surgical expertise, while policymakers explore pathway reforms to broaden patient access.

These regional insights underscore the imperative of tailoring commercial approaches to the unique operational, regulatory, and cultural nuances of each geographic cluster.

Analyzing Competitive Investments in Innovation Collaborations and Market Expansion Efforts to Strengthen Device Portfolios and Clinical Reach

Leading medical device companies have intensified their focus on minimally invasive glaucoma surgery through product innovation, strategic collaborations, and geographic expansion. Several organizations have leveraged proprietary platforms to enhance microcatheter performance, proprietary stent materials, and biocompatible coatings, underscoring the competitive emphasis on incremental differentiation.

Some firms have pursued licensing agreements or acquisitions to integrate complementary technologies, broadening their procedural portfolios and reinforcing clinical engagement through joint research initiatives. These partnerships have also facilitated access to key markets by aligning with local distributors or contract manufacturers that possess established regulatory and commercial capabilities.

Meanwhile, manufacturers with robust R&D pipelines are advancing next-generation candidates through clinical evaluations, aiming to address persistent challenges such as outflow patency over time and long-term biostability. At the same time, entities with established sales networks are optimizing surgeon training programs and digital support tools to accelerate adoption and foster evidence generation.

Collectively, these competitive strategies reflect a deepening commitment to expanding procedural utility, improving patient safety, and strengthening market presence in an increasingly dynamic environment.

Outlining Strategic Imperatives for Collaborative Innovation Evidence Generation and Operational Excellence to Drive Sustainable Competitive Advantage

Industry leaders should prioritize cross-functional collaboration to align clinical insights with engineering initiatives, ensuring that next-generation devices address nuanced surgical challenges. By integrating surgeon feedback early in the development cycle, organizations can preemptively tailor device features to real-world procedural requirements.

Strategic partnerships with academic institutions and surgical centers will continue to be instrumental in generating robust clinical evidence, driving both regulatory approvals and payer acceptance. In addition, expanding digital platforms for virtual training and tele-mentoring can broaden procedural proficiency across diverse practice settings, supporting faster adoption curves and enhancing patient safety.

On the operational front, diversifying manufacturing footprints and bolstering supply chain agility will mitigate exposure to tariff fluctuations and logistical disruptions. Concurrently, engaging with policy stakeholders can help shape reimbursement frameworks that recognize the long-term economic value of minimally invasive procedures.

Ultimately, a holistic strategy that combines clinical excellence, robust data generation, and adaptable commercial models will equip industry players to capitalize on emerging opportunities and navigate impending challenges.

Detailing the Comprehensive Mixed-Methods Approach Integrating Expert Interviews Regulatory Analyses and Supply Chain Evaluation

This research employed a mixed-methods approach, combining qualitative expert interviews with quantitative assessments of regulatory filings and clinical trial registries. Foundational insights were derived from in-depth discussions with leading ophthalmic surgeons, healthcare administrators, and policy advisors to capture nuanced perspectives on procedural preferences, payer dynamics, and patient outcomes.

Secondary research included systematic review of peer-reviewed journals, conference proceedings, and publicly available patent databases to map technological trajectories and identify emerging device candidates. Regulatory frameworks across key territories were analyzed to ascertain approval timelines, classification pathways, and post-market surveillance requirements.

Additionally, supply chain and tariff impact analyses drew on trade data, customs documentation, and corporate disclosures to evaluate cost drivers and mitigation strategies. Data triangulation ensured that findings are corroborated across multiple independent sources, reinforcing the reliability and relevance of conclusions.

This methodology underpins a comprehensive understanding of the minimally invasive glaucoma surgery device sector, balancing depth of insight with broad contextual awareness.

Synthesizing Technological Evidence and Operational Agility as Cornerstones for Charting Future Success in Glaucoma Device Innovation

In summary, the minimally invasive glaucoma surgery device sector stands at an inflection point characterized by rapid technological refinement, evolving payer expectations, and shifting trade policies. As manufacturers refine microincisional platforms across diverse mechanistic pathways, the imperative to generate robust clinical evidence has never been greater.

Simultaneously, stakeholders must deftly navigate regional regulatory nuances and tariff landscapes while bolstering supply chain resilience. Strategic collaborations and targeted commercial models will be essential to unlocking new patient populations and sustaining adoption momentum.

Looking ahead, the intersection of innovation, evidence generation, and operational agility will define competitive success. Organizations that proactively integrate these elements into cohesive strategies will be best positioned to shape the future of glaucoma management and deliver meaningful outcomes across global healthcare systems.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Mechanism
    • Canaloplasty
      • iTrack
      • OMNI System
    • Subconjunctival Filtration
      • Preserflo Microshunt
      • Xen Gel Stent
    • Suprachoroidal Shunts
      • Cypass
      • Istent Supra
    • Trabecular Micro-Bypass
      • Hydrus Microstent
      • IStent
      • Kahook Dual Blade
      • Trabectome
  • End User
    • Ambulatory Surgery Centers
    • Hospital
    • Ophthalmic Clinics
  • Distribution Channel
    • Direct Tender
    • Distributor
  • Indication
    • Ocular Hypertension
    • Primary Open Angle Glaucoma
    • Secondary Glaucoma
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Alcon Inc.
  • Glaukos Corporation
  • Johnson & Johnson Vision Care, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Ivantis, Inc.
  • AbbVie Inc.
  • MicroSurgical Technology, Inc.
  • New World Medical, Inc.
  • Oertli Instrumente AG
  • Istar Medical S.A.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rapid rise in combined cataract and ab interno MIGS procedures for glaucoma management leading to streamlined surgical workflows
5.2. Commercial launch of drug-eluting suprachoroidal microstents offering sustained intraocular pressure control without daily drops
5.3. Growing surgeon preference for trabecular meshwork bypass stents driven by simplicity and favorable safety profile in early glaucoma
5.4. Increasing investment in smart intraoperative imaging integration to enhance precision of MIGS device placement and procedural outcomes
5.5. Expansion of reimbursement coverage for office-based MIGS treatments improving patient access in key developed markets
5.6. Development of next-generation bioresorbable implants aimed at reducing foreign body reactions and long-term tissue scarring
5.7. Surge in clinical trials evaluating combination therapies of MIGS devices with sustained-release pharmacologics for enhanced efficacy
5.8. Entry of emerging-market manufacturers offering cost-competitive MIGS alternatives spurring pricing pressure on established players
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Minimally Invasive Glaucoma Surgery Devices Market, by Mechanism
8.1. Introduction
8.2. Canaloplasty
8.2.1. iTrack
8.2.2. OMNI System
8.3. Subconjunctival Filtration
8.3.1. Preserflo Microshunt
8.3.2. Xen Gel Stent
8.4. Suprachoroidal Shunts
8.4.1. Cypass
8.4.2. Istent Supra
8.5. Trabecular Micro-Bypass
8.5.1. Hydrus Microstent
8.5.2. IStent
8.5.3. Kahook Dual Blade
8.5.4. Trabectome
9. Minimally Invasive Glaucoma Surgery Devices Market, by End User
9.1. Introduction
9.2. Ambulatory Surgery Centers
9.3. Hospital
9.4. Ophthalmic Clinics
10. Minimally Invasive Glaucoma Surgery Devices Market, by Distribution Channel
10.1. Introduction
10.2. Direct Tender
10.3. Distributor
11. Minimally Invasive Glaucoma Surgery Devices Market, by Indication
11.1. Introduction
11.2. Ocular Hypertension
11.3. Primary Open Angle Glaucoma
11.4. Secondary Glaucoma
12. Americas Minimally Invasive Glaucoma Surgery Devices Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Minimally Invasive Glaucoma Surgery Devices Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Minimally Invasive Glaucoma Surgery Devices Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Alcon Inc.
15.3.2. Glaukos Corporation
15.3.3. Johnson & Johnson Vision Care, Inc.
15.3.4. Santen Pharmaceutical Co., Ltd.
15.3.5. Ivantis, Inc.
15.3.6. AbbVie Inc.
15.3.7. MicroSurgical Technology, Inc.
15.3.8. New World Medical, Inc.
15.3.9. Oertli Instrumente AG
15.3.10. Istar Medical S.A.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2024 VS 2030 (%)
FIGURE 6. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 8. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET: RESEARCHAI
FIGURE 24. MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET: RESEARCHSTATISTICS
FIGURE 25. MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET: RESEARCHCONTACTS
FIGURE 26. MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY CANALOPLASTY, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY CANALOPLASTY, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY ITRACK, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY ITRACK, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY OMNI SYSTEM, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY OMNI SYSTEM, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY CANALOPLASTY, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY CANALOPLASTY, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUBCONJUNCTIVAL FILTRATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUBCONJUNCTIVAL FILTRATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PRESERFLO MICROSHUNT, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PRESERFLO MICROSHUNT, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY XEN GEL STENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY XEN GEL STENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUBCONJUNCTIVAL FILTRATION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUBCONJUNCTIVAL FILTRATION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUPRACHOROIDAL SHUNTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUPRACHOROIDAL SHUNTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY CYPASS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY CYPASS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY ISTENT SUPRA, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY ISTENT SUPRA, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUPRACHOROIDAL SHUNTS, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUPRACHOROIDAL SHUNTS, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY HYDRUS MICROSTENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY HYDRUS MICROSTENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY ISTENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY ISTENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY KAHOOK DUAL BLADE, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY KAHOOK DUAL BLADE, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECTOME, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECTOME, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY OPHTHALMIC CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY OPHTHALMIC CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DIRECT TENDER, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DIRECT TENDER, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY OCULAR HYPERTENSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY OCULAR HYPERTENSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PRIMARY OPEN ANGLE GLAUCOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PRIMARY OPEN ANGLE GLAUCOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SECONDARY GLAUCOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SECONDARY GLAUCOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY CANALOPLASTY, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY CANALOPLASTY, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUBCONJUNCTIVAL FILTRATION, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUBCONJUNCTIVAL FILTRATION, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUPRACHOROIDAL SHUNTS, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUPRACHOROIDAL SHUNTS, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY CANALOPLASTY, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY CANALOPLASTY, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUBCONJUNCTIVAL FILTRATION, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUBCONJUNCTIVAL FILTRATION, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUPRACHOROIDAL SHUNTS, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUPRACHOROIDAL SHUNTS, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 105. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 106. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 107. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY CANALOPLASTY, 2018-2024 (USD MILLION)
TABLE 108. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY CANALOPLASTY, 2025-2030 (USD MILLION)
TABLE 109. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUBCONJUNCTIVAL FILTRATION, 2018-2024 (USD MILLION)
TABLE 110. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUBCONJUNCTIVAL FILTRATION, 2025-2030 (USD MILLION)
TABLE 111. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUPRACHOROIDAL SHUNTS, 2018-2024 (USD MILLION)
TABLE 112. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUPRACHOROIDAL SHUNTS, 2025-2030 (USD MILLION)
TABLE 113. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
TABLE 114. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
TABLE 115. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 116. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 117. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 118. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 119. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 120. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 121. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 122. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 123. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY CANALOPLASTY, 2018-2024 (USD MILLION)
TABLE 124. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY CANALOPLASTY, 2025-2030 (USD MILLION)
TABLE 125. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUBCONJUNCTIVAL FILTRATION, 2018-2024 (USD MILLION)
TABLE 126. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUBCONJUNCTIVAL FILTRATION, 2025-2030 (USD MILLION)
TABLE 127. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUPRACHOROIDAL SHUNTS, 2018-2024 (USD MILLION)
TABLE 128. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUPRACHOROIDAL SHUNTS, 2025-2030 (USD MILLION)
TABLE 129. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
TABLE 130. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
TABLE 131. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 132. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 133. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 134. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 135. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 136. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY CANALOPLASTY, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY CANALOPLASTY, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUBCONJUNCTIVAL FILTRATION, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUBCONJUNCTIVAL FILTRATION, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUPRACHOROIDAL SHUNTS, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUPRACHOROIDAL SHUNTS, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 151. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 152. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY CANALOPLASTY, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY CANALOPLASTY, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUBCONJUNCTIVAL FILTRATION, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUBCONJUNCTIVAL FILTRATION, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUPRACHOROIDAL SHUNTS, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUPRACHOROIDAL SHUNTS, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 167. ARGENTINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 168. ARGENTINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY CANALOPLASTY, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY CANALOPLASTY, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUBCONJUNCTIVAL FILTRATION, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUBCONJUNCTIVAL FILTRATION, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUPRACHOROIDAL SHUNTS, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUPRACHOROIDAL SHUNTS, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY CANALOPLASTY, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY CANALOPLASTY, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUBCONJUNCTIVAL FILTRATION, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUBCONJUNCTIVAL FILTRATION, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUPRACHOROIDAL SHUNTS, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUPRACHOROIDAL SHUNTS, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 198. UNITED KINGDOM MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 200. UNITED KINGDOM MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 202. UNITED KINGDOM MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 203. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 204. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 205. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY CANALOPLASTY, 2018-2024 (USD MILLION)
TABLE 206. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY CANALOPLASTY, 2025-2030 (USD MILLION)
TABLE 207. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUBCONJUNCTIVAL FILTRATION, 2018-2024 (USD MILLION)
TABLE 208. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUBCONJUNCTIVAL FILTRATION, 2025-2030 (USD MILLION)
TABLE 209. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUPRACHOROIDAL SHUNTS, 2018-2024 (USD MILLION)
TABLE 210. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUPRACHOROIDAL SHUNTS, 2025-2030 (USD MILLION)
TABLE 211. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
TABLE 212. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
TABLE 213. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 214. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 215. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 216. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 217. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 218. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 219. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 220. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 221. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY CANALOPLASTY, 2018-2024 (USD MILLION)
TABLE 222. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY CANALOPLASTY, 2025-2030 (USD MILLION)
TABLE 223. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUBCONJUNCTIVAL FILTRATION, 2018-2024 (USD MILLION)
TABLE 224. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUBCONJUNCTIVAL FILTRATION, 2025-2030 (USD MILLION)
TABLE 225. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUPRACHOROIDAL SHUNTS, 2018-2024 (USD MILLION)
TABLE 226. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUPRACHOROIDAL SHUNTS, 2025-2030 (USD MILLION)
TABLE 227. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
TABLE 228. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
TABLE 229. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 232. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 233. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 234. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY CANALOPLASTY, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY CANALOPLASTY, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUBCONJUNCTIVAL FILTRATION, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUBCONJUNCTIVAL FILTRATION, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUPRACHOROIDAL SHUNTS, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUPRACHOROIDAL SHUNTS, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
TABLE 245. RUSSIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 246. RUSSIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 247. RUSSIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 248. RUSSIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 249. RUSSIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 250. RUSSIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 251. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 252. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 253. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY CANALOPLASTY, 2018-2024 (USD MILLION)
TABLE 254. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY CANALOPLASTY, 2025-2030 (USD MILLION)
TABLE 255. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUBCONJUNCTIVAL FILTRATION, 2018-2024 (USD MILLION)
TABLE 256. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUBCONJUNCTIVAL FILTRATION, 2025-2030 (USD MILLION)
TABLE 257. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUPRACHOROIDAL SHUNTS, 2018-2024 (USD MILLION)
TABLE 258. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUPRACHOROIDAL SHUNTS, 2025-2030 (USD MILLION)
TABLE 259. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
TABLE 260. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
TABLE 261. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 262. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 263. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 264. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 265. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 266. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDI

Samples

Loading
LOADING...

Companies Mentioned

  • Alcon Inc.
  • Glaukos Corporation
  • Johnson & Johnson Vision Care, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Ivantis, Inc.
  • AbbVie Inc.
  • MicroSurgical Technology, Inc.
  • New World Medical, Inc.
  • Oertli Instrumente AG
  • Istar Medical S.A.

Table Information